The myxobacteria, long a source of fascination due to their sophisticated, social lifestyles, are now increasingly recognized as multi-producers of promising natural products. Here we provide an overview of the bioactivities and modes-of-action of these secondary metabolites, with an emphasis on potential clinical applications. Highlights of metabolite modes-of-action: case studies 3.1 Soraphen: an inhibitor of acetyl-CoA carboxylase 3.2 Corallopyronin, myxopyronin, ripostatin, and sorangicin: inhibitors of bacterial RNA polymerase 3.3 Disorazol: a potential anti-cancer agent 3.4 Argyrin: a proteasome inhibitor 4 Outlook 5 Acknowledgements 6 References